Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 1,501–1,600 of 1,676
Estudios que cambiaron la práctica de la medicina familiar en los últimos 20 años
Sguiglia, S., & Vietto, V. (2020) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v23i1.4271
McNeal, C. J., & Peterson, A. L. H. (2020) · Cited by 2
Review of LDL-C Lowering with Focus on New and Emerging Agents
Brinton (2020) · The Journal of Family Practice · doi:10.12788/jfp.0070
Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician
Bakris (2020) · The Journal of Family Practice · doi:10.12788/jfp.0072
A New Era in Asthma Management: Assessment of Asthma Control
Murphy, M. (2020) · The Journal of Family Practice · doi:10.12788/jfp.0061
Prädiktoren für die Entwicklung einer Myopathie unter Simvastatin
Diener, H. (2021) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-021-2023-4
Determination of Diabetes and Dyslipidemia Goals in the Management of Diabetes
Jain, R. K., Olejas, S., Davey, S., et al. (2021) · Book Publisher International (a part of SCIENCEDOMAIN International) · doi:10.9734/bpi/nfmmr/v14/12685d
Hwang, Y. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_9
Anderson, J. L. C. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.192996734
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-62939-0_9-1
Kardiovaskuläre Prophylaxe: Wenn man Surrogatmarker „therapiert“
Erdmann, E. (2015) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2015.09.18.08
Pharmacology for cardiovascular nurses
Keenan, J., Khatib, R., McKee, G., Ruppar, T. M., & Wilson, F. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198849315.003.0012
High-density lipoprotein cholesterol — friend or enemy?
Murzakhanova, A. F., OSLOPOV, V. N., Sergienko, K. S., Khazova, E. V., & OSLOPOVA, J. V. (2022) · Kazan medical journal · doi:10.17816/kmj2022-79
“Исследование HPS2-Thrive показало, что добавление ниацина в терапию, снижающую уровень ХС ЛПНП на основе статинов, значительно снизило риск серьёзных сосудистых заболеваний, но это увеличило частоту побочных эффектов: желудочно-кишечных осложнений, кровотечений, заболеваний опорно-двигательного аппарата, повышенной ча…”
Padala, S. K., Sidhu, M. S., & Boden, W. E. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_70-1
Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management
Cupido, A. J., Stoekenbroek, R. M., & Kastelein, J. J. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-45457-9_23
HDL function metrics and clinical outcomes in prospective cohort studies
Jia, C. (2022) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.210078636
Pande, R. L., & Creager, M. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00148-7 · Cited by 5
Huxley, R., Taylor, R. J., & Dobson, A. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00390-8
Garg, A., & Sharma, A. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.064
McGiness, T. P., Holbert, H., Hentrich, L., & Waite, L. H. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.lipid_overview
Smith, C. K., Sheehan, J. P., & Ulchaker, M. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-04414-9_127
Cowan, H. (2018) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2018.13.2.60
Nicotinic acid and derivatives
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01146-x
Dyslipidemias and other cardiometabolic risk factors in older adults
Arai, H. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198701590.003.0096
Smith, C. K., Sheehan, J. P., & Ulchaker, M. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_127-1
Risks of adverse events with niacin/laropiprant
(2014) · Reactions Weekly · doi:10.1007/s40278-014-2546-2
Khan, N., & Williams, H. (2015) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2015.10.8.394
Ginsberg, H. N., Khavandi, M., & Reyes‐Soffer, G. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_2-2
Wehling, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820493-1.00027-1
Waite, L. H., & McGiness, T. P. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.hyperlipidemia_overview
Fazio, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736866539.793567220
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-18539-2_19
The Role of level and function of High Density Lipoprotein (HDL) in Cardiovascular Diseases
آقاسی زاده, م., غیور مبرهن, م., کاظمی, ط., آوان, ا., & Miri‐Moghaddam, E. (2020) · مجله علمی دانشگاه علوم پزشکی بیرجند · doi:10.32592/jbirjandunimedsci.2020.27.2.100
The relation between coronary artery disease and newly diagnosed dysglycemia
Cam, T. D., & Ton, T. T. (2022) · Perfusion · doi:10.1177/02676591221113970
“14 Abnormalities were also observed in the functional state of the heart and its anatomy: left ventricular re-modeling, accompanied by cavity dilatation, hypertrophic or pseudonormal type of diastole dysfunction.”
BackgroundMasson, W. M., Lobo, M., Barbagelata, L., Bagnati, R. P., OBERTI, P. F., Falconi, M. L., Krauss, J. G., Parcerisa, F., & Pizarro, R. (2022) · Revista Argentina de Cardiología · doi:10.7775/rac.es.v90.i3.20516 · Cited by 4
Biomarkers in Disease: Diabetes Methods, Discoveries and Applications
de Carvalho, L. S. F., Asari, A. I. A., Teles, B. S. B. D. S., Chaves‐Filho, A. B., & Yoshinaga, M. Y. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81303-1_20-1
Abordagem atual das dislipidemias
Juliani, F. C., & Rocha, V. Z. (2021) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2021.20.4.20-31
Biomarkers in Disease: Diabetes Methods, Discoveries, and Applications
de Carvalho, L. S. F., Asari, A. I. A., Teles, B. S. B. D. S., Filho, A. D. B. C., & Yoshinaga, M. Y. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-08014-2_20
Agricultural Development in Asia
Nath, V. (1970) · Pacific Affairs · doi:10.2307/2754223
Har HDL-kolesterol og triglyserider en rolle i hjerte- og karsykdom?
Christensen, J. J. (2015) · Norsk tidsskrift for ernæring · doi:10.18261/ntfe.13.4.7
Nutraceuticals for targeting NAD+ to restore mitochondrial function
Garten, A., & Lavery, G. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90256-4.00019-9
Hibernation or Transformation? Challenges in Cardiovascular Drug Development
Mercanoğlu, G., & Mercanoğlu, F. (2022) · Frontiers in cardiovascular drug discovery · doi:10.2174/9789815036909122060005
Fricker, J. (2018) · EMJ Cardiology · doi:10.33590/emjcardiol/10314733
Evaluation of Autologous Plasma Gel in Tear Trough Deformity
Elmahdi, S. W., Shaker, E. S. E., Mahmoud, W. H., & Amin, T. E.-S. (2023) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2023/v35i54966 · Cited by 1
Eriş, D. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2576
Schwartz, G. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00036-4
Catapano, A. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00013-3 · Cited by 2
Liu, R., & Cheng, W. (2023) · Research Square · doi:10.21203/rs.3.rs-2916582/v1
MODERN APPROACHES IN THE TREATMENT OF DYSLIPIDEMIA AND FUTURE PERSPECTIVES
TABUKASHVILI, R., KAPETIVADZE, V., KAPETIVADZE, I., Silagadze, T. K., Kuparadze, M., MAGLAPERIDZE, Z., & LAZASHVILI, T. (2023) · EXPERIMENTAL & CLINICAL MEDICINE GEORGIA · doi:10.52340/jecm.2023.02.10
“ორივე კვლევამ აჩვენა გვერდითი ეფექტის სიჭარბე ნიცინის ჯგუფში პლაცებოსთან შედარებით [23,24].”
Omari, M., & Alkhalil, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113665
Managing Stable Coronary Artery Disease in Diabetes
Koulouridis, I., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_23
Lipoproteins and Ischemic Stroke in Diabetes
Quispe, R., Goestch, M., Kazzi, B. E., Zghyer, F., Abovich, A., Zeiler, S. R., Martin, S. S., Toth, P. P., & Jones, S. R. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_19
Masson, W. M. (2023) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v26i3.7072
Moore, M. K., Jones, G., McCormick, S., Williams, M. J. A., & Coffey, S. (2023) · medRxiv · doi:10.1101/2023.09.20.23295872 · Cited by 9
Clarke, R., & Baigent, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00092-2
Krishnamurthy, H. A., Bhangari, V. S., & Sandesh, L. (2023) · Journal of Medical and Scientific Research · doi:10.17727/jmsr.2023/11-39
Zhao, H., Jiang, W., Song, S., Lyu, L., Chang, C., Zhao, Y., Wu, B., Wang, L., & Girgenti, M. J. (2023) · Research Square · doi:10.21203/rs.3.rs-3229244/v1 · Cited by 1
Han, D., Shi, L., Yu, J., & Na, L. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21666
Schrick, M. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10181
Niacin-Induced Syncope in a Middle-Aged Male: When an Over-the-Counter Vitamin Goes Wrong
Huang, J., Ahmed, I. A., Balogun, A., et al. (2023) · Cureus · doi:10.7759/cureus.50454
“Another trial, the HPS2-THRIVE (Heart Protection Study 2-treatment of HDL to reduce the incidence of vascular events) study [13], enrolled 25,673 adults with vascular disease and compared the effects of 2 g of extended-release niacin with 40 mg of laropiprant (a selective DP1 receptor antagonist…”
BackgroundTherapies in Disorders of Lipid Metabolism and Obesity
Akuffo Quarde, M. D. (2023) · Wiley eBooks · doi:10.1002/9781119863564.ch7
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-62932-1_9
Ischaemic Heart Disease in Diabetes
Lehrke, M., & Marx, N. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch49
Benyaminov, F., & Sinha, A. G. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_14
The influence of lipoproteina(a) on cardio-vascular diseases
Maj-Dziedzic, M., Brzozowska, A., Sikora, M., Zarzycka, M., Plewniok, I., Dubiel, J., Maj, A., Śmietana, G., Warno, M., & Kozik, W. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.54.013 · Cited by 1
Espoirs et place prochaine potentielle des inhibiteurs de la Lp(a)
Guédon, A. F., Ghrenassia, E., Cohen, A. A., & Boccara, F. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.003
The Protective Impact of Residual Cholesterol on Mortality Risk in Oldest OldPreprint
Yang, L., Wang, J., Xu, Z., Xu, L., Chen, C., Wei, Y., Zhou, J., Liu, S., Xia, Y., Zhang, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4069002/v1
Reilly, N. A., Dekkers, K. F., Molenaar, J., Arumugam, S., Kuipers, T. B., Ariyürek, Y., Hoeksema, M. A., Jukema, J. W., & Heijmans, B. T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.15.585315
“Nevertheless, most triglyceride influencing therapies, such as fibrates or niacin, have little cardiovascular benefit 5-9 .”
BackgroundTherapeutic Targeting of High-Density Lipoprotein Metabolism
deGoma, E. M., & Rader, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00044-x
Schwartz, G. G., & Do, R. Q. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00039-6
Agreement between mega-trials and smaller trials: a meta-research studyPreprint
Kastrati, L., Raeisi‐Dehkordi, H., Llanaj, E., Quezada‐Pinedo, H. G., Khatami, F., Ahanchi, N. S., Llane, A., Meçani, R., Muka, T., & Ioannidis, J. P. A. (2024) · medRxiv · doi:10.1101/2024.05.09.24307122
Sepehri, Z., Sargazi, A., Sarhaddi, F., Sepehri, M., Moghaddam, Y. A., Shahraki, K., Kiani, Z., Fard, N. E., & Mohammadi, Z. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-55474-2_2
PCSK-9 inhibitors improve cardiovascular events after PCI in patients with chronic kidney diseasePreprint
Xu, H., & Li, J. (2024) · Research Square · doi:10.21203/rs.3.rs-4836351/v1
Futatsugi, A., Tozuka, M., Horiuchi, Y., Ohkawa, R., & Kosho, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-74699-5 · Cited by 1
Niacin (Niacin) and clinical utility, don't be misled by recent niacin (Niacin) metabolite report
Superko, H. R., & Garrett, B. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.001
Pedro‐Botet, J., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Martínez‐Montoro, J. I., de Victoria, E. O.-M., Ribalta, J., Sánchez‐Margalet, V., & Pérez, A. (2024) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2024.09.001
Shao, L., Zhi, A., Li, M., Zhang, Y., Jiang, S., Zhang, J., Yang, K., Yang, E., Zhu, X., Cheng, Y., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2511410 · Cited by 1
Optimizing long-term prevention of cardiovascular disease with reinforcement learningPreprint
Zhou, Y., Luo, R., Blais, J. E., Tan, K. C. B., Lui, D. T. W., Yiu, K. H., Lai, F. T. T., Wan, E. Y. F., Cheung, C., Wong, I. C. K., et al. (2024) · medRxiv · doi:10.1101/2024.12.09.24318697
(2000) · Time to knit · doi:10.1016/j.ccol.2015.05.016
(2000) · Time to knit · doi:10.1016/s1155-1941(19)84494-3
(2000) · Time to knit · doi:10.1016/j.ccol.2015.05.003
(2000) · Time to knit · doi:10.1016/j.ccol.2015.05.014
(2000) · Time to knit · doi:10.1016/j.ccol.2023.02.007
(2000) · Time to knit · doi:10.1016/j.ccol.2023.02.008
(2000) · Time to knit · doi:10.1016/s1155-1941(17)77032-1
Detection and Treatment of Chronic Complications
Soe, K. K., & Gunasekaran, U. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch05
Pedro‐Botet, J., Arrieta, F., Botana, M., Gimeno-Orna, J. A., Martínez‐Montoro, J. I., de Victoria, E. O.-M., Ribalta, J., Sánchez‐Margalet, V., & Pérez, A. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.101523 · Cited by 2
Horiuchi, Y., Hirayama, S., Hori, A., Ichikawa, Y., Soda, S., Seino, U., Sekihara, K., Ueno, T., Fukushima, Y., Kubono, K., et al. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251328154
Angilov, V. I., Osmanova, N. J., Vakhitova, S. R., et al. (2025) · Russian Journal of Dentistry · doi:10.17816/dent646337
Wang, H.-X., Bi, H., Shangguan, X., Chen, Z., Huang, R., Chen, X., & Cai, Y. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2536343 · Cited by 1
Platelet Thromboxane A2 and Prostaglandin Receptors
Petrucci, G., Farhoud, M. A., & Habib, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-96340-7_17
Association between a reduction in triglyceride levels and risk of cardiovascular events
Yamashita, I., Ishii, M., Tokai, T., Ikebe, S., Yamanouchi, Y., Nakamura, T., & Tsujita, K. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100647
“In the AIM-HIGH [27], HPS2-THRIVE [28], and ACCORD-lipid [29] trials, triglyceride levels decreased to below 150 mg/dL in the treatment groups following intervention; however, none of these studies demonstrated a reduction in cardiovascular event risk.”
Frazier, C. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch21
Cardiovascular Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch17
Remnant Cholesterol as a Predictor of Target-Vessel Failure in Patients With In-Stent Restenosis
Kong, X.-H., Lv, Z.-H., Wang, Y.-F., Sun, Y.-D., Xu, T., You, W., Meng, P.-N., Wu, X., Wu, Z., Jia, H.-B., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm43867
Rosman, A., Yusof, A. K. B. M., Hadi, H. A., Yong, D. T. W., Amran, I. M., Goay, S. E., Sulaiman, N. Y., Choong, S. Y., Thum, C. H., Ray, K. K., et al. (2025) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2025.17
Cardiovascular Risk Factor Dyslipidemia
Lebherz, C., & Lehrke, M. (2025) · Springer eBooks · doi:10.1007/978-3-662-69938-6_9
Medical Management of Serum Lipids and Coronary Heart Disease
Ababneh, B. A., Dadu, R. T., Pokharel, Y., Jones, P. H., & Ballantyne, C. M. (2015) · Cardiovascular medicine · doi:10.1007/978-1-4471-2828-1_3
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.